Free Trial
NASDAQ:CMPX

Compass Therapeutics Q4 2024 Earnings Report

Compass Therapeutics logo
$2.09 -0.01 (-0.48%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.18 +0.10 (+4.55%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Compass Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Compass Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Compass Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Compass Therapeutics Earnings Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Compass Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email.

About Compass Therapeutics

Compass Therapeutics (NASDAQ:CMPX), a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

View Compass Therapeutics Profile

More Earnings Resources from MarketBeat